Vertex Pharma huge outperformer in American biotech sector

In the recent years Vertex Pharma had a very positive price momentum. Because of the huge return over the past 5 years of 161 percent the share belongs to the top of the biotech companies. Shares of the sector yielded the past 5 years a gain of approximately 191 percent.

Momentum biotech sector

The sector trades now at 60 times the earnings per share. The sector trades at 10,31 times the book value per share. Since 2012 the sector has a profit of 191 percent and since 2007 a profit of 598 percent.

For this year Vertex Pharma's revenue will be around 3,57 billion USD. This is according to the average of the analysts' estimates. This is quite more than 2017's revenue of 3,05 billion USD.

Historical revenues and results Vertex Pharma plus estimates 2019

The analysts expect for 2019 a net profit of 1,12 billion USD. According to most of the analysts the company will have a profit per share for this book year of 4,33 USD. The price/earnings-ratio is then 39,24.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a moderate 0,5 percent.

Newest target prices around 223 USD

Oppenheimer & Co, Morgan Stanley and Cowen and Company recently provided recommendations for the stock.

Vertex Pharma's market capitalization is based on the number of outstanding shares around 43,03 billion USD. The Vertex Pharma stock was the past 12 months quite volatile. Since last May the stock is 13 percent higher. This year the stock price moved between 144 and 196 dollar.

Historical stock prices Vertex Pharma

On Tuesday the stock closed at 169,91 USD.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.